Home » Stocks » Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc. (YMAB)

Stock Price: $41.41 USD -0.33 (-0.79%)
Updated Jul 9, 2020 10:38 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.65B
Revenue (ttm) n/a
Net Income (ttm) -91.27M
Shares Out 39.76M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $41.41
Previous Close $41.74
Change ($) -0.33
Change (%) -0.79%
Day's Open 41.69
Day's Range 41.22 - 43.37
Day's Volume 12,276
52-Week Range 14.16 - 50.49

More Stats

Market Cap 1.65B
Enterprise Value 1.46B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 39.76M
Float 21.09M
EPS (basic) -2.5
EPS (diluted) -2.50
FCF / Share -2.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.23M
Short Ratio 8.02
Short % of Float 7.50%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.51
Revenue n/a
Operating Income -93.50M
Net Income -91.27M
Free Cash Flow -83.64M
Net Cash 183.68M
Net Cash / Share 4.62
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.98%
ROE -60.68%
ROIC 2,027.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(11.88% upside)
Current: 41.41
Target: 46.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-83.00-43.23-19.24-17.04
Net Income-81.03-43.27-19.16-17.06
Shares Outstanding35.1828.7719.4014.09
Earnings Per Share-2.30-1.50-0.99-1.21
Operating Cash Flow-73.50-41.23-15.87-11.17
Capital Expenditures-1.97-0.23--
Free Cash Flow-75.46-41.46-15.87-11.17
Cash & Equivalents20714890.5216.90
Total Debt2.23---
Net Cash / Debt20514890.5216.90
Book Value19914182.1512.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Y-mAbs Therapeutics, Inc.
Country United States
Employees 65
CEO Claus Juan Møller-San Pedro

Stock Information

Ticker Symbol YMAB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: YMAB
IPO Date September 21, 2018


Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.